Editorial: What is clinical utility and why should we care?

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 6, 2010, Pages 729-733

  Lesko, L J ^a   Zineh, I ^a   Huang, S M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; EDITORIAL; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; METHODOLOGY; PATIENT CARE; PRIORITY JOURNAL; CLINICAL MEDICINE; CLINICAL TRIAL (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENETICS;

CLINICAL MEDICINE; CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT CARE; PHARMACOGENETICS;

EID: 78449311355     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.229     Document Type: Editorial

References (27)

1. Huang, S-M. & Temple, R. Is this the drug or dose for you? -Impact of ethnic factors in global drug development, regulatory review and clinical practice. Clin. Pharmacol. Ther. 84, 287-294 (2008).
2. Temple, R. Enrichment of clinical study populations. Clin. Pharmacol. Ther. 88, 774-778 (2010).
3. Woodcock, J. Molecular medicine: how, what and when? Clin. Pharmacol. Ther. 82, 376-378 (2007).
4. Lesko, L.J. & Zineh, I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 11, 507-512 (2010).
5. Evans, B.J. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era. Clin. Pharmacol. Ther. 88, 749-751 (2010).
6. Quinn, B. Payers and the assessment of clinical utility for companion diagnostics. Clin. Pharmacol. Ther. 88, 751-754 (2010).
7. Umscheid, C.A. Maximizing the clinical utility of comparative effectiveness research. Clin. Pharmacol. Ther. 88, 876-879 (2010).
8. Burns, D.K. Developing pharmacogenetic evidence throughout clinical development. Clin. Pharmacol. Ther. 88, 867-870 (2010)
9. Mudd, P.N. Jr., Groenendaal, H., Bush, M.A. & Schmith, V.D. Probabilistic risk analysis: improving early drug development decision making. Clin. Pharmacol. Ther. 88, 871-875 (2010).
10. Holliday, E.G., Scott, R. & Attia, J. Evidence-based medicine in the era of biomarkers: teaching a new dog old tricks? Clin. Pharmacol. Ther. 88, 740-742 (2010).
11. Woodcock, J. The prospects for personalized medicine in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
12. Zerhouni, E. Medicine: the NIH roadmap. Science 302, 63-72 (2003).
13. Roses, A. Personalized medicine: elusive dream or imminent reality-a commentary. Clin. Pharmacol. Ther. 81, 801-805 (2007).
14. Epstein, R.S. Pharmacy benefit managers: evaluating clinical utility in the real world. Clin. Pharmacol. Ther. 88, 880-882 (2010).
15. March, J.S., Silva, S.G., Compton, S., Shapiro, M., Califf, R. & Krishnan, R. The case for practical clinical trials in psychiatry. Am. J. Psychiatr. 162, 836-846 (2005).
16. Carleton, B. Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations. Clin. Pharmacol. Ther. 88, 757-759 (2010).
17. Lesko, L.J. Personalized medicine: elusive dream or imminent reality. Clin. Pharmacol. Ther. 81, 807-816 (2007).
18. Woodcock, J. Assessing the clinical utility of diagnostics used in drug therapy. Clin. Pharmacol. Ther. 88, 765-773 (2010).
19. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin. Pharmacol. Ther. 88, 862-866 (2010).
20. Zineh, I. & Lesko, L.J. Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. Personalized Med. 6, 359-361 (2009).
21. Smart, A. A multi-dimensional model of clinical utility. Int. J. Qual. Health Care 18, 377-382 (2006).
22. Grosse, S. & Khoury, M. What is the clinical utility of genetic testing? Genet. Med. 8, 448-450 (2006).
23. O'Kane, D. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but. Clin. Pharmacol. Ther. 88, 746-748 (2010).
24. Hockett, R.D. & Close, S.L. Regulation of laboratory-developed tests: the case for utilizing professional associations. Clin. Pharmacol. Ther. 88, 743-745 (2010).
25. US Department of Health and Human Services. Secretary's Advisory Committee on Genetics, Health and Society-Coverage and reimbursement of genetic tests and services (February 2006).
26. Foster, M.W. et al. Evaluating the utility of personal genomic information. Genet. Med. 11, 570-574 (2009).
27. Shen, B. & Hwang, J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin. Pharmacol. Ther. 88, 754-756 (2010).